Completed PHASE1/PHASE2 INTERVENTIONAL NCT00288925

Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

Sponsor: Zeria Pharmaceutical

Conditions Pancreatic Cancer

Interventions Z-360

Updated 5 times since 2017 Last updated: May 29, 2009 Started: Sep 30, 2005 Primary completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by Zeria Pharmaceutical and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zeria Pharmaceutical

Data source: Zeria Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom